tradingkey.logo

Myriad Genetics Inc

MYGN
查看详细走势图
6.550USD
-0.010-0.15%
收盘 12/24, 13:00美东报价延迟15分钟
609.80M总市值
亏损市盈率 TTM

Myriad Genetics Inc

6.550
-0.010-0.15%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.15%

5天

-4.80%

1月

-11.25%

6月

+34.77%

今年开始到现在

-52.22%

1年

-52.01%

查看详细走势图

TradingKey Myriad Genetics Inc股票评分

单位: USD 更新时间: 2025-12-23

操作建议

Myriad Genetics Inc当前公司基本面数据相对健康,增长潜力较大。当前估值合理,在医疗设备与耗材行业排名92/208位。机构持股占比非常高,近一月多位分析师给出公司评级为持有。最高目标价8.06。中期看,股价处于平稳状态。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Myriad Genetics Inc评分

相关信息

行业排名
92 / 208
全市场排名
221 / 4568
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 13 位分析师
持有
评级
8.064
目标均价
+14.05%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Myriad Genetics Inc亮点

亮点风险
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
业绩高增长
公司营业收入稳步增长,连续3年增长23.47%
估值高估
公司最新PE估值-1.51,处于3年历史高位
机构减仓
最新机构持股92.00M股,环比减少10.78%
PRFDX持仓
明星投资者PRFDX持仓,最新持仓市值21.15K
活跃度增加
近期活跃度增加,过去20天平均换手率1.07

Myriad Genetics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Myriad Genetics Inc简介

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.
公司代码MYGN
公司Myriad Genetics Inc
CEORaha (Samraat S)
网址https://myriad.com/

常见问题

Myriad Genetics Inc(MYGN)的当前股价是多少?

Myriad Genetics Inc(MYGN)的当前股价是 6.550。

Myriad Genetics Inc的股票代码是什么?

Myriad Genetics Inc的股票代码是MYGN。

Myriad Genetics Inc股票的52周最高点是多少?

Myriad Genetics Inc股票的52周最高点是15.470。

Myriad Genetics Inc股票的52周最低点是多少?

Myriad Genetics Inc股票的52周最低点是3.760。

Myriad Genetics Inc的市值是多少?

Myriad Genetics Inc的市值是609.80M。

Myriad Genetics Inc的净利润是多少?

Myriad Genetics Inc的净利润为-127.30M。

现在Myriad Genetics Inc(MYGN)的股票是买入、持有还是卖出?

根据分析师评级,Myriad Genetics Inc(MYGN)的总体评级为持有,目标价格为8.064。

Myriad Genetics Inc(MYGN)股票的每股收益(EPS TTM)是多少

Myriad Genetics Inc(MYGN)股票的每股收益(EPS TTM)是-4.347。
KeyAI